跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD19 CAR-T cell
首页
药物
CD19 CAR-T cell
CD19 CAR-T cell
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20
EP 3240805 B1
申请人: UNIV CALIFORNIA
优先权: 2014
EP
US
WO
19 件公开
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US 11207349 B2
申请人: CELLULAR BIOMEDICINE GROUP HK LTD
优先权: 2020
CN
EP
US
WO
16 件公开
TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
EP 3539986 B1
申请人: NOVARTIS AG
优先权: 2013
CN
EP
US
WO
12 件公开
CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP 4065157 A1
申请人: NOVARTIS AG
优先权: 2019
CN
EP
US
7 件公开
FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD22 AND USE THEREOF
EP 4174093 A4
申请人: NANJING IASO BIOTECHNOLOGY CO LTD
优先权: 2020
CN
EP
US
WO
5 件公开
CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES
EP 4259650 A1
申请人: OSPEDALE PEDIATRICO BAMBINO GESÙ
优先权: 2020
CN
EP
US
WO
5 件公开
METHODS FOR TREATING LUPUS NEPHRITIS USING ANTI-CD19 CAR-T CELL THERAPIES
EP 4608418 A1
申请人: KYVERNA THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
5 件公开
CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
EP 4334357 A1
申请人: FUNDACIO DE RECERCA CLINIC BARCELONA INST DINVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
优先权: 2021
EP
US
WO
5 件公开
CAR MOLECULE, CELL OR EXOSOME CONTAINING SAME, AND USE THEREOF
EP 4653467 A1
申请人: WUHAN ZHAOZHI BIOTECHNOLOGY CO LTD
优先权: 2023
CN
EP
US
WO
4 件公开
METHODS FOR TREATING STIFF PERSON SYNDROME AND MYASTHENIA GRAVIS USING ANTI-CD19 CAR-T CELL THERAPIES
EP 4754239 A1
申请人: KYVERNA THERAPEUTICS INC
优先权: 2023
CN
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈